X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Autogene cevumeran (RO7198457) is a messenger RNA (mRNA)-based personalized cancer vaccine, which is being evaluated in combination with atezolizumab for the treatment of resected pancreatic ductal adenocarcinoma.
Lead Product(s): Autogene Cevumeran,Atezolizumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: RO7198457
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody candidate jointly developed by BioNTech and OncoC4. BNT316/ONC-392 is currently in late-stage clinical development in combination with lutetium (177Lu) vipivotide tetraxetan in patients with mCRPC.
Lead Product(s): Gotistobart,Lutetium Vipivotide Tetraxetan
Therapeutic Area: Oncology Product Name: ONC-392
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: OncoC4
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
The collaboration aims to support Autolus in the development of BNT211 (CLDN6 CAR-T/CLDN6 CAR-T(A)) for the treatment of relapsed or refractory advanced solid tumors such as ovarian cancer, sarcoma, testicular cancer, endometrial cancer and gastric cancer.
Lead Product(s): BNT211,CARVac
Therapeutic Area: Oncology Product Name: BNT211
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Autolus Therapeutics
Deal Size: $250.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration February 08, 2024
Details:
DB-1305 (BNT325) is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the TROP2. It is being evaluated in phase 1/2 clinical trials for the treatment of patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer.
Lead Product(s): BNT325
Therapeutic Area: Oncology Product Name: DB-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Duality Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
BNT323 (DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2. It is under phase 3 clinical development for the treatment of metastatic breast cancer.
Lead Product(s): DB-1303
Therapeutic Area: Oncology Product Name: BNT323
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Duality Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms to discover two undisclosed targets of preclinical investigational monoclonal antibodies for BioNTech to develop next-generation therapeutic product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: $20.0 million
Deal Type: Agreement January 11, 2024
Details:
BNT323 (DB-1303) is a next-generation Topoisomerase 1 inhibitor, ADC candidate targeting HER2, a cell surface protein. It is under phase 1/2 clinical development for the treatment of HER2-expressing advanced endometrial cancer.
Lead Product(s): DB-1303
Therapeutic Area: Oncology Product Name: BNT323
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Duality Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
BioNTech will be developing, manufacturing and commercializing PM8002, a bispecific antibody candidate being evaluated in patients with advanced solid tumors, globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.
Lead Product(s): PM8002
Therapeutic Area: Oncology Product Name: PM8002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Biotheus
Deal Size: $1,055.0 million Upfront Cash: $55.0 million
Deal Type: Licensing Agreement November 07, 2023
Details:
COMIRNATY® (tozinameran), a mRNA based COVID-19 Vaccine, which is investigated in combination with BNT-161 for the treatment of Influenza and COVID-19.
Lead Product(s): Tozinameran,BNT-161
Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
BNT122 is a mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran, which is investigated for the treatment of resected pancreatic ductal adenocarcinoma.
Lead Product(s): Autogene Cevumeran,Atezolizumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: BNT122
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
